Urology Flashcards
RCC
Most common renal cancer, also have TCC, SCC.
Adenocarcinoma of the renal cortex, mainly affecting upper pole.
Spread direct (to tissues, IVC, adrenal glands), haematogenous (to bone, liver, brain, lungs), lymphatic.
Differentials- UTI, urological malignancy, renal stones.
RCC-
RF
Features
Smoking, obesity, HTN, ADPKD, horseshoe kidney, dialysis (*30), male, increasing age, carcinogen exposure.
Presents with visible/non visible haematuria. Also flank mass, pain or general lethargy/weight loss. Stauffer syndrome; non metastatic hepatic dysfunction.
Paraneoplastic- Renin-HTN, PTH-HyperCa, EPO-PC.
NB MOST CASES PRESENT INCIDENTALLY
RCC- Investigation
Abdo/pelvis CT with contrast- Gold standard.
May also biopsy.
Bloods- U+Es, LFTs, Ca, CRP. Urinalysis and cytology.
RCC- Management
Partial/radical (including lymphatics and perinephric fat) nephrectomy, if organ confined.
If contraindicated then radiofrequency ablation, monitor.
Metastasis- not responsive to chemo; +/-surgical removal and immunotherapy preferred.
Bladder cancer
Originates at bladder wall lining, commonly TCC but also SSC and rarer adenocarcinoma.
Classified into non-muscle invasive-NMI, MI or locally advanced/metastatic- beyond the bladder.
Differentials- prostate/renal cancer, renal stone, UTI.
Bladder cancer-
RF
Features
Smoking, exposure too carcinogens are main RF- FHx not really relevant. increasing age more common. Also male.
Present with (non)/visible haematuria. Also can get recurrent UTIs and LUT symptoms i.e. frequency.
Bladder cancer- Investigation
Urgent cystoscopy, if can suspicious lesion switch to rigid cystoscopy.
Take biopsy. If superficial lesion then remove during rigid cystoscopy via TURBT, if invasive wait for biopsy.
Bladder cancer- Management
NMI- TURBT woth adjuvant Mitomycin C (reduce recurrence but not progression) or BCG (more commonly in superficial- reduce recurrence and progression)with neoadjuvant cisplatin. (Increased recurrence with superficial). If high risk disease/non responsive to treatment then radical cystectomy.
MI- Radical cystectomy- replace bladder with ileal conduit or bladder reconstruction.
Locally advance/metastatic- Chemo
Testicular cancer
Most common cancer in male 20-40yrs.
Can be NGC (Leydig/sertoli, usually benign) or germ cell (malignant).
Germ cell can be semionomas or non-seminomatous.
Differentials- hydrocoele, epididymal cyst, epididymitis, haematoma.
Testicular cancer-
RF
Features
RF- undescended testes, FHx, previous testicular malignancy.
Features; unilateral painless lump in the testes. Lump will feel firm, fixed and irregular on palpation- cannot transilluminate. If metastatic then may get back pain, dyspnoea, weight loss.
Testicular cancer- Investigations
USS and tumour markers (Beta-HCG) initially.
Then with CT contrast of chest, abdomen and pelvis.
Don’t take a biopsy as can lead to seeding of tumour.
Stage I- Contained to testes
Stage II- Infra-diaphragmatic LN involved.
Stage III- Supra and infra-D LN involved.
Stage IV- Extra-lymphatic metastasis.
Testicular cancer- Management
Confirmed cases need discussing for best treatment.
Conduct fertility assessment before treating- radio/chemotherapy harmful.
Treat with surgery (orchidectomy), radio/chemo.
NSGCT- Treat with surgery then follow with adjuvant chemo if high risk.
Metastatic- Poor prognosis is one chemo cycle, otherwise a few cycles.
Seminomas- Surgeryand surveillance.
Metastatic- Radio/chemo
Prostate cancer-
Common cancer in men. Usually adenocarcinoma (AC) affecting the peripheral zone of the prostate. Can be either acinar AC (more common), affecting the cells lining the prostate or ductal- cells linign the ducts.
Differentials; BPH, bladder cancer, kidney stones, pyelonephritis, prostatitis.
Prostate cancer-
RF
Features
Age, FHx, ethnicity (Afro-Car) . Also smoking, obesity, BRAC1/2 gene, DM.
LUTS initially. Once advanced localised; haematuria, haematospermia, suprapubic pain, loin pain, bone pain, weight loss etc.
Prostate cancer-
Investigations
DRE- palpable, firm irregular mass.
PSA- Although not specific.
Biopsy- transperineal/trasnsrectal. Repeat biopsy if persistent abnormal PSA/DRE.
Grade with Gleason score.
Image with mp-MRI. Stage with CT abdo-pelvis.
Prostate cancer-
Management
Look at risk:
Low- Monitor, consider radical if progression.
Intermediate/high- Monitor (If intermediate)/radical.
Metastatic- Chemo/ anti-hormonal agents.
Surveillance- Repeat PSA 3/12, DRE 6/12-1yr, biopsy 1-3yrs.
Surgery- Prostatectomy, and remove seminal vesicles, LN.